|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
Skin Picking Disorder (SPD) affects up to 10% of the general population, causing significant socioeconomic damage in 75% of affected individuals. It is characterized by the repeated habit of touching the skin itself, causing or aggravating wounds, with difficulty in controlling the habit. It is associated with anxiety disorders in about 20% of cases and with depressive disorder in about 50%. Patients with SPD have difficulties in regulating emotions, being more vulnerable to having their mental symptoms aggravated in face of stressful situations, such as the current coronavirus-19 pandemia. Among the treatments available to SPD, cognitive behavioral therapy is the only intervention superior to placebo, and there is still no medication approved by the FDA indicated specifically to SPD. The effectiveness of cognitive behavioral therapy was assessed in a randomized clinical trial with Brazilian patients with SPD, but its long-term benefit has not yet been evaluated. Additionally, telemedicine interventions can be effective and used during pandemia, but the effectiveness of internet delivered cognitive behavioral therapy for SPD is not clear yet.
Description: The skin picking improvement after intervention will be assessed by the change in the Global Clinical Impression Scale, applied by blinded evaluators.Measure: Change in Global Clinical Impression Scale Time: 2 weeks
Description: Anxiety severity improvement after the intervention, assessed thru the Beck Anxiety InventoryMeasure: Change in Beck Anxiety Inventory Time: 2 weeks
Description: Depression severity improvement after the intervention, assessed thru the Beck Depression InventoryMeasure: Change in Beck Depression Inventory Time: 2 weeks
Description: Impact of Skin Picking in the life of the patient, assessed thru the Skin Picking Impact ScaleMeasure: Change of Skin Picking Impact Scale Time: 2 weeks
Description: Assess the correlation of emotional regulation, thru the DERS-36 (difficulties in emotional regulation scale), with the different skin picking subtypes (focused or automatic), thru the Milwaukee scale of dermatillomania subtypes.Measure: Change of emotional regulation Time: 2 weeks
Description: Evaluate change in anxiety symptoms thru the Hamilton anxiety scale applied by blinded evaluatorsMeasure: Change in Hamilton Anxiety Scale Time: 2 weeks
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports